Wedbush reiterated their outperform rating on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a research report report published on Monday morning, Benzinga reports. They currently have a $5.00 price objective on the stock. Wedbush also issued estimates for Elevation Oncology’s Q4 2023 earnings at ($0.26) EPS, FY2023 earnings at ($1.21) EPS, Q1 2024 […]
Related Keywords
, Annandale Capital , Elevation Oncology Company Profile , Virtu Financial , Millennium Management , Elevation Oncology Inc , Jpmorgan Chase Co , Renaissance Technologies , Elevation Oncology , Free Report , Moderate Buy , Oncology Stock Down , Get Free Report , Elevation Oncology Daily , Nasdaq Elev , Belev , Medical , Reiterated Rating , Wedbush ,
comparemela.com © 2020. All Rights Reserved.